The latest news from academia, regulators
research labs and other things of interest
Posted: May 22, 2013
Germ-fighting nanomedicine vaccine system makes great strides in delivery
(Nanowerk News) A novel vaccine study from South Dakota State University (SDSU) will headline the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The meeting takes place Monday, May 20 - Wednesday, May 22 at the Sheraton San Diego Hotel and Marina.
"The main goal of a vaccine is to stimulate the immune system to fight against a pathogen that causes the disease", explained Dr. Hemachand Tummala, assistant professor of Pharmaceutical Sciences at SDSU. "We want to make a delivery system that mimics pathogens in stimulating the immune system but not cause infection."
Tummala and his doctoral student, Sunny Kumar, used inulin acetate taken from a fiber derived from tubers, such as dahlias or chicory. "The fiber is natural, inexpensive and easily accessible", Tummala stated. "Most importantly, it acts as a PAMP [pathogen-associated molecular pattern]. We made pathogen-like nanoparticles with inulin acetate and incorporated pathogen-related antigens inside them." Tummala explained, "Once the antigen presenting cells sense these particles as pathogens, they eat them and process them as PAMPs." This then aggravates the immune system.
The researchers then tested the technology in preventing a viral disease. Tummala collaborated with Dr. Victor Huber, assistant professor and infectious disease specialist at the Sanford School of Medicine, whose research focuses on influenza.
The researchers then tested the efficiency of the vaccine delivery system in mice against a lethal challenge of the 2009 pandemic H1N1 flu virus. One group of mice was not immunized, while the others received a vaccine containing one or two antigens. Within eight days, 90 percent of the unvaccinated mice died. Those who received one antigen contracted the flu, and all but one recuperated. None of those who received the vaccine with two antigens acquired the flu.
"The low cost of the technology, estimated at one or two dollars per dose, also makes it suitable for animal vaccines," Tummala explained. He is working with other SDSU researchers to apply the delivery to sheep and swine vaccines.
Dr. Tummala and his team will also receive the 2013 American Association of Pharmaceutical Scientists Innovation in Biotechnology Award for their research on Tuesday, May 21.
Source: American Association of Pharmaceutical Scientists
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
Check out these other trending stories on Nanowerk: